Pharmaceutical company Servier has inaugurated a novel production unit at its manufacturing site in Normandy, France.
The unit will be dedicated to the production of an active ingredient used in one of the company's venous disease-targeting therapeutics.
At the new production unit, Servier will use its novel manufacturing process to boost production efficiency, while ensuring regulatory compliance.
Through this expansion, the company aims to enhance and secure its active pharmaceutical ingredient (API) production capacity, allowing it to meet the needs of patients with venous diseases worldwide.
Part of Servier's 2030 strategic plan, Servier has constructed a methanisation plant to recycle processed waste into gas — facilitating the site's goals of self-sufficiency in terms of energy requirements.
On top of this, an effluent treatment plant has been installed, reducing the site's environmental footprint.
“These new industrial facilities mark a strategic step in line with our 2030 ambition," notes Olivier Laureau, President of Servier.
"By combining innovation and industrial excellence, we are scaling up our ability to sustainably meet patient needs, while bolstering our health sovereignty in France and Europe.”
Normandy isn't the only site that Servier has invested in, as its industrial site in Budapest has recently experienced an €80m revamp — resulting in increased capacity for the production of the same API being produced at the new Normandy unit.
According to the Group, it has invested more than €230m into API production capacity expansion in the last six years, contributing to the European healthcare autonomy.
[Image credit: Servier]